表紙
市場調査レポート

画像診断関連の提携動向:条件・契約内容

Global Diagnostic Imaging Partnering Terms and Agreements 2010 to 2016

発行 Current Partnering, a division of Wildwood Ventures Limited 商品コード 309765
出版日 ページ情報 英文 557 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
画像診断関連の提携動向:条件・契約内容 Global Diagnostic Imaging Partnering Terms and Agreements 2010 to 2016
出版日: 2016年06月02日 ページ情報: 英文 557 Pages
概要

当レポートでは、世界の画像診断分野(CT・内視鏡・MRI・超音波・X線など)における企業提携(パートナーシップ)の締結動向やその内容(提携条件)について分析し、近年の企業提携の動向や特徴、平均的な取引条件、代表的な取引事例、大手製薬企業の契約動向、近年の提携取引一覧(種類別・開発段階別・適応症別)とその内訳といった情報を盛り込んで、概略以下の内容でお届けいたします。

エグゼクティブ・サマリー

第1章 イントロダクション

第2章 画像診断関連の企業提携の締結動向

  • イントロダクション
  • 近年の画像診断関連の提携動向
  • 大手製薬企業による画像診断関連の提携活動
  • 画像診断関連の提携に最も積極的な企業
  • 画像診断関連の提携:業種別
  • 画像診断関連の提携:契約の種類別
  • 画像診断関連の提携:疾患の種類別
  • 画像診断関連の提携:技術の種類別
  • 画像診断関連の提携:平均的な取引条件
    • 支払総額
    • 前払い金
    • マイルストーン払い
    • ロイヤルティ料率
  • 画像診断関連の提携の構造
    • ケーススタディ:Vaso DiagnosticsとGE Healthcareの場合(2010年7月)

第3章 画像診断関連の代表的な資本取引

  • イントロダクション
  • 画像診断関連の代表的な資本取引と取引金額

第4章 大手製薬企業の画像診断関連の資本取引

  • イントロダクション
  • 各種提携契約の活用方法
  • 大手製薬企業の画像診断関連の提携契約一覧(全14社分)

第5章 画像診断関連の提携契約の一覧

  • イントロダクション
  • 企業名順(A〜Z:全33社分)
  • 取引の種類別
    • 資産購入
    • 共同開発
    • 契約サービス
    • 流通
    • ライセンス契約
    • 製造
    • マーケティング
    • オプション
    • プロモーション
    • 調停
    • 二次ライセンス
    • 供給
    • 技術移転
    • 契約終了
  • 治験段階別
    • 前臨床
    • 第III相
    • 認証中
    • 上市済み
  • 治療用域別
    • 心血管疾患
    • 皮膚疾患
    • 胃腸障害
    • 血液疾患
    • 入院治療
    • 腫瘍

第6章 画像診断関連の提携契約の締結傾向:診断技術別

  • イントロダクション
  • 提携契約の締結傾向:診断技術別

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: CP21041

The ‘Global Diagnostic Imaging Partnering Terms and Agreements 2010 to 2016’ report provides comprehensive understanding and unprecedented access to the diagnostic imaging partnering agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter diagnostic imaging partnering deals. This report provides details of the latest diagnostics agreements announced in the healthcare sectors, covering:

  • Imaging
  • CT
  • Endoscope
  • Molecular and nuclear
  • PET
  • SPECT
  • MRI
  • Ultrasound
  • X ray
  • Angiography
  • Fluoroscopy
  • Mammography

This report provides an overview of diagnostic imaging dealmaking, the common clauses, rights and options in the partnering agreement, and also a comprehensive review of deals signed in since 2010.

This report provides a comprehensive and detailed review of all diagnostic imaging deals announced since 2010. The comprehensive agreements chapter is organized by company A-Z, stage of development at signing, deal type, and therapy focus. Each deal title links via Weblink to an online version of the actual deal at Current Agreements deals and alliances database, providing easy access to each deal on demand. Where available, the full deal contract document is also provided and indicated by a document symbol.

Contract documents provide unsurpassed access to the detail of a deal normally announced in brief summary through a press release. Detailed analysis of a contract allow better understanding of the terms agreed between the parties, and importantly the basis under which monies and licensing rights are exchanged.

The initial chapters of this report provide an orientation of Diagnostic Imaging dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Diagnostic Imaging dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Diagnostic Imaging deals since 2010. Deals are listed by headline value, signed by big pharma, most active Diagnostic Imaging dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Diagnostic Imaging dealmaking with a brief summary followed by a comprehensive listing of Diagnostic Imaging deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of Diagnostic Imaging partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of Diagnostic Imaging partnering deals signed and announced since Jan 2010. The chapter is organized by specific Diagnostic Imaging technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by Diagnostic Imaging partnering company A-Z, deal type definitions and Diagnostic Imaging partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Diagnostic Imaging partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Diagnostic Imaging technologies and products.

Key benefits

‘Global Diagnostic Imaging Partnering Terms and Agreements’ provides the reader with the following key benefits:

  • In-depth understanding of diagnostic deal trends since 2010
  • Analysis of the structure of diagnostic agreements with numerous real life case studies
  • Comprehensive access to over 900 actual diagnostic imaging deals entered into by the world's biopharma companies
  • Detailed access to actual diagnostic contracts enter into by the leading biopharma companies
  • Insight into the terms included in a diagnostic agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

‘Global Diagnostic Imaging Partnering Terms and Agreements’ is intended to provide the reader with an in-depth understanding of the diagnostic imaging trends and structure of deals entered into by leading companies worldwide.

‘Global Diagnostic Imaging Partnering Terms and Agreements’ includes:

  • Trends in diagnostic imaging dealmaking in the biopharma industry since 2010
  • Analysis of diagnostic imaging deal structure
  • Case studies of real-life diagnostic imaging deals
  • Access to over 900 diagnostic imaging contract documents
  • The leading diagnostic imaging deals by value since 2010
  • Most active diagnostic imaging dealmakers since 2010
  • The leading diagnostic imaging partnering resources

In ‘Global Diagnostic Imaging Partnering Terms and Agreements’, the available contracts are listed by:

Headline value Stage of development at signing Deal component type Specific therapy target Specific technology target

Each deal title links to online deal records of actual diagnostic imaging partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The ‘Global Diagnostic Imaging Partnering Terms and Agreements’ report provides comprehensive access to available contract documents for over 900 diagnostic imaging deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise diagnostic rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Diagnostic Imaging dealmaking

  • 2.1. Introduction
  • 2.2. Diagnostic Imaging partnering over the years
  • 2.3. Most active Diagnostic Imaging dealmakers
  • 2.4. Diagnostic Imaging partnering by deal type
  • 2.5. Diagnostic Imaging partnering by therapy area
  • 2.6. Deal terms for Diagnostic Imaging partnering
    • 2.6.1. Diagnostic Imaging partnering headline values
    • 2.6.2. Diagnostic Imaging deal upfront payments
    • 2.6.3. Diagnostic Imaging deal milestone payments
    • 2.6.4. Diagnostic Imaging royalty rates

Chapter 3 - Leading Diagnostic Imaging deals

  • 3.1. Introduction
  • 3.2. Top Diagnostic Imaging deals by value

Chapter 4 - Most active Diagnostic Imaging dealmakers

  • 4.1. Introduction
  • 4.2. Most active Diagnostic Imaging dealmakers
  • 4.3. Most active Diagnostic Imaging partnering company profiles

Chapter 5 - Diagnostic Imaging contracts dealmaking directory

  • 5.1. Introduction
  • 5.2. Diagnostic Imaging contracts dealmaking directory

Chapter 6 - Diagnostic Imaging dealmaking by technology type

Chapter 7 - Partnering resource center

  • 7.1. Online partnering
  • 7.2. Partnering events
  • 7.3. Further reading on dealmaking

Appendices

  • Appendix 1 - Diagnostic Imaging deals by company A-Z
  • Appendix 2 - Diagnostic Imaging deals by stage of development
    • Discovery
    • Preclinical
    • Phase I
    • Phase II
    • Phase III
    • Regulatory
    • Marketed
    • Formulation
  • Appendix 3 - Diagnostic Imaging deals by deal type
    • Asset purchase
    • Bigpharma outlicensing
    • Co-development
    • Collaborative R&D
    • Co-market
    • Co-promotion
    • CRADA
    • Cross-licensing
    • Development
    • Distribution
    • Equity purchase
    • Evaluation
    • Grant
    • Joint venture
    • Licensing
    • Litigation
    • Manufacturing
    • Manufacturing - OEM
    • Marketing
    • Option
    • Promotion
    • Research
    • Settlement
    • Spin out
    • Sub-license
    • Supply
    • Technology transfer
    • Termination
  • Appendix 4 - Diagnostic Imaging deals by therapy area
    • Breast
    • Cardiovascular
    • Central Nervous System
    • Dental
    • Dermatology
    • Gastrointestinal
    • Genetic disorders
    • Genitourinary
    • Gynaecology
    • Hematology
    • Hospital care
    • Immunology
    • Infectives
    • Musculoskeletal
    • Obstetrics
    • Oncology
    • Ophthalmics
    • Orphan disease
    • Pediatrics
    • Psychiatry
    • Respiratory
    • Appendix 5 -Deal type definitions
    • About Wildwood Ventures
    • Current Partnering
    • Current Agreements
    • Recent report titles from Current Partnering

Table of figures

  • Figure 1: Diagnostic Imaging partnering since 2010
  • Figure 2: Active Diagnostic Imaging dealmaking activity- 2010 to 2016
  • Figure 3: Diagnostic Imaging partnering by deal type since 2010
  • Figure 4: Diagnostic Imaging partnering by disease type since 2010
  • Figure 5: Diagnostic Imaging deals with a headline value
  • Figure 6: Diagnostic Imaging deals with an upfront value
  • Figure 7: Diagnostic Imaging deals with a milestone value
  • Figure 8: Diagnostic Imaging deals with a royalty rate value
  • Figure 9: Top Diagnostic Imaging deals by value since 2010
  • Figure 10: Most active Diagnostic Imaging dealmakers 2010 to 2016
  • Figure 11: Online partnering resources
  • Figure 12: Forthcoming partnering events
Back to Top